Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.35 |
| ▸ | MMP9 | P14780 | 4/20 | 0.35 |
| ▸ | MMP8 | P22894 | 4/20 | 0.35 |
| ▸ | MMP13 | P45452 | 4/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26510481 | 0.90 | GBA1 (0.38) | GBA1DGAT1F2RL1OPRM1OPRD1 | |
| SCHEMBL16645298 | 0.84 | GLS (0.42) | GBA1DGAT1F2RL1DRD2MMP2 | |
| SCHEMBL2358722 | 0.83 | GBA1 (0.38) | GBA1DGAT1F2RL1OPRM1OPRD1 | |
| SCHEMBL22396008 | 0.82 | DGAT1 (0.37) | GBA1DGAT1F2RL1OPRM1OPRD1 | |
| SCHEMBL26701585 | 0.79 | NOTUM (0.38) | GBA1DGAT1OPRM1OPRD1OPRK1 | |
| SCHEMBL22381488 | 0.78 | NOTUM (0.41) | GBA1DGAT1MMP2MMP9MMP8 | |
| SCHEMBL26770649 | 0.77 | F2RL1 (0.40) | DGAT1F2RL1OPRM1OPRD1OPRK1 | |
| SCHEMBL22151452 | 0.77 | DGAT1 (0.39) | DGAT1F2RL1OPRM1OPRD1OPRK1 | |
| SCHEMBL22151451 | 0.77 | DGAT1 (0.39) | DGAT1F2RL1OPRM1OPRD1OPRK1 | |
| SCHEMBL29324043 | 0.76 | NOTUM (0.45) | GBA1DGAT1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178609-A1 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178609-A1 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | SGMS2, SGMS1, DEGS1 | GBA1 374/4885DGAT1 209/4885F2RL1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.